Works cited by this work

199 works

Work: Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?

1. Neoantigens: promising targets for cancer therapy

   Na Xie, Guobo Shen, Wei Gao +3

   Review article20236 citations

   ABIABI:AkademIndex/openalex/2026.other.102931

2. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies

   Xinyi Xiao, Shengkang Huang, Sifei Chen +4

   Review article20215 citations

   ABIABI:AkademIndex/openalex/2026.other.102897

3. Regulatory mechanisms of PD-1/PD-L1 in cancers

   Xin Lin, Kuan Kang, Pan Chen +5

   Article20245 citations

   ABIABI:AkademIndex/openalex/2026.other.102973

4. Exploring treatment options in cancer: tumor treatment strategies

   Beilei Liu, Hongyu Zhou, Licheng Tan +2

   Review article20245 citations

   ABIABI:AkademIndex/openalex/2026.other.102979

5. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors

   Lei Peng, Giacomo Sferruzza, Luojia Yang +2

   Review article20245 citations

   ABIABI:AkademIndex/openalex/2026.other.102983

6. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells

   Levi J. Rupp, Kathrin Schumann, Kole T. Roybal +4

   Article20174 citations

   ABIABI:AkademIndex/openalex/2026.other.020478

7. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection

   Justin Eyquem, Jorge Mansilla‐Soto, Theodoros Giavridis +6

   Article20174 citations

   ABIABI:AkademIndex/openalex/2026.other.102842

8. CAR-T Cell Performance: How to Improve Their Persistence?

   Gina López-Cantillo, Claudia Urueña, Bernardo Camacho +1

   Review article20224 citations

   ABIABI:AkademIndex/openalex/2026.other.102912

9. Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells

   Miyuki Tanaka, Haruko Tashiro, Bilal Omer +9

   Article20173 citations

   ABIABI:AkademIndex/openalex/2026.other.020471

10. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

    Donald M. O’Rourke, MacLean P. Nasrallah, Arati Desai +18

    Article20173 citations

    ABIABI:AkademIndex/openalex/2026.other.020482

11. Engineering CAR-T Cells for Next-Generation Cancer Therapy

    Mihe Hong, Justin Clubb, Yvonne Y. Chen

    Review article20203 citations

    ABIABI:AkademIndex/openalex/2026.other.082243

12. Bispecific T‐cell engagers for cancer immunotherapy

    Amelia M. Huehls, Tiffany A. Coupet, Charles L. Sentman

    Review article20143 citations

    ABIABI:AkademIndex/openalex/2026.other.102829

13. Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance

    Andriy Marusyk, Michalina Janiszewska, Kornélia Polyák

    Review article20203 citations

    ABIABI:AkademIndex/openalex/2026.other.102873

14. Expanded natural killer cells augment the antimyeloma effect of daratumumab, bortezomib, and dexamethasone in a mouse model

    Jaya Lakshmi Thangaraj, Seo-Yeon Ahn, Sung‐Hoon Jung +12

    Article20213 citations

    ABIABI:AkademIndex/openalex/2026.other.102891

15. Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors

    Zhenguang Wang, Na Li, Kaichao Feng +14

    Article20213 citations

    ABIABI:AkademIndex/openalex/2026.other.102893

16. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results

    Changsong Qi, Jifang Gong, Jian Li +23

    Article20223 citations

    ABIABI:AkademIndex/openalex/2026.other.102908

17. Long-term outcomes following CAR T cell therapy: what we know so far

    Kathryn M. Cappell, James N. Kochenderfer

    Review article20233 citations

    ABIABI:AkademIndex/openalex/2026.other.102938

18. Intratumoral Delivery of Chimeric Antigen Receptor T Cells Targeting CD133 Effectively Treats Brain Metastases

    Agata Kieliszek, Daniel Mobilio, Deepak Upreti +10

    Article20233 citations

    ABIABI:AkademIndex/openalex/2026.other.102948

19. Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma

    Christine E. Brown, Behnam Badie, Michael E. Barish +14

    Article20152 citations

    ABIABI:AkademIndex/openalex/2026.other.020402

20. Interleukin-7 Mediates Selective Expansion of Tumor-redirected Cytotoxic T Lymphocytes (CTLs) without Enhancement of Regulatory T-cell Inhibition

    Serena Perna, Daria Pagliara, Aruna Mahendravada +4

    Article20132 citations

    ABIABI:AkademIndex/openalex/2026.other.020432

21. Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells

    Omkar U. Kawalekar, Roddy S. O’Connor, Joseph A. Fraietta +11

    Article20162 citations

    ABIABI:AkademIndex/openalex/2026.other.020449

22. Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells

    Lenka V. Hurton, Harjeet Singh, Amer Najjar +12

    Article20162 citations

    ABIABI:AkademIndex/openalex/2026.other.020466

23. Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors

    Rachel Grosser, Leonid Cherkassky, Navin K. Chintala +1

    Review article20192 citations

    ABIABI:AkademIndex/openalex/2026.other.020534

24. Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies

    Gregory L. Beatty, Andrew R. Haas, Marcela V. Maus +9

    Article20132 citations

    ABIABI:AkademIndex/openalex/2026.other.082777

25. The inducible caspase-9 suicide gene system as a “safety switch†to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells

    Tessa Gargett, Michael P. Brown

    Review article20142 citations

    ABIABI:AkademIndex/openalex/2026.other.102821